ClinicalTrials.Veeva

Menu

The OPTI Study in Spain Looks at the History Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Inhaled Steroids.

Boehringer Ingelheim logo

Boehringer Ingelheim

Status

Completed

Conditions

Pulmonary Disease, Chronic Obstructive

Treatments

Drug: Inhaled corticosteroid

Study type

Observational

Funder types

Industry

Identifiers

NCT03611777
1237-0070

Details and patient eligibility

About

This non-Interventional, descriptive, cross-sectional cohort and multicentre study will be conducted with COPD patients attended at Spanish Primary Care offices.

Enrollment

901 patients

Sex

All

Ages

40+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Written informed consent prior to participation
  2. Female and male patient ≥ 40 years of age
  3. Chronic Obstructive Pulmonary Disease (COPD) diagnosis more than 2 years before the study visit
  4. Previously confirmed Chronic Obstructive Pulmonary Disease (COPD) diagnosis (post-bronchodilator FEV1/FVC ratio <70%)
  5. Clinical data available 2 years before the study visit
  6. Ability to complete CAT - COPD Assessment Test

Exclusion criteria

  1. Current participation in any clinical trial involving a drug or device
  2. A moderate or severe exacerbation (requiring oral corticosteroid, antibiotics or hospitalisation) during the study visit or within 4 weeks before the study visit

Trial design

901 participants in 1 patient group

subjects with Pulmonary Disease, Chronic Obstructive
Treatment:
Drug: Inhaled corticosteroid

Trial documents
2

Trial contacts and locations

169

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems